Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results